Lacripep
Ocular Surface Disease / Dry Eye Disease (Primary Sjögren's Syndrome)
Key Facts
About TearSolutions
TearSolutions is a private, pre-revenue biotech founded in 2021 and based in Charlottesville, Virginia, targeting the large and growing market for dry eye disease (DED) and ocular surface disease (OSD). Its core innovation is Lacripep, a synthetic peptide mimetic of the endogenous protein Lacritin, designed to address the underlying biological deficiency in OSD. The company has completed a positive Phase I/II trial in primary Sjögren's Syndrome and is preparing for a Phase IIb study in moderate/severe dry eye, positioning it in a competitive but high-need therapeutic area.
View full company profileAbout TearSolutions
TearSolutions is a private, pre-revenue biotech founded in 2021 and based in Charlottesville, Virginia, targeting the large and growing market for dry eye disease (DED) and ocular surface disease (OSD). Its core innovation is Lacripep, a synthetic peptide mimetic of the endogenous protein Lacritin, designed to address the underlying biological deficiency in OSD. The company has completed a positive Phase I/II trial in primary Sjögren's Syndrome and is preparing for a Phase IIb study in moderate/severe dry eye, positioning it in a competitive but high-need therapeutic area.
View full company profile